PRiME Next-Generation Precision Medicine at the University of Toronto

What PRiME Next-Generation Precision Medicine at the University of Toronto does

PRiME Next-Generation Precision Medicine is the University of Toronto's institutional strategic initiative in precision medicine, formally established in 2019 and operated out of the Leslie Dan Faculty of Pharmacy at 144 College Street, Toronto. Its mission is to align multidisciplinary research efforts in drug discovery, delivery, diagnostics, and disease biology through three translational "Precision X" hubs: Precision Aging, Precision Oncology, and Precision Women's Health. The initiative coordinates a community of over 50 faculty members and close to 100 trainees spanning basic scientists, clinical researchers, biomedical engineers, and entrepreneurs, and its programs include an annual symposium (now in its 7th iteration), a PhD-level Collaborative Specialization, a fellowship program, the Building a Biotech Venture (BBTV) pitch competition, and the federally funded BioHubNet biomanufacturing talent initiative led by Scientific Director Molly Shoichet.

PRiME does not sell commercial products. Its economic model is grant- and donation-funded: cumulative disclosed grants include $18.9M CAD from the Government of Canada (BioHubNet, 2024) and $3.6M from the University of Toronto's Medicine by Design initiative (2019), supplemented by industry sponsorships for the annual symposium from Bayer, Amgen, Novartis, Moderna, Genome Canada, OBIO, Frontier/Versant, CDD Vault, and STEMCELL Technologies, as well as philanthropic donations channeled through U of T's giving platform. Distribution occurs exclusively through the U of T and affiliated-hospital network (UHN, SickKids, Women's College Hospital, OICR), with no external pricing model other than a modest per-attendee symposium fee ranging from $25 to $100 CAD. Strategic commercialization pathways are routed through partnership channels - notably Toronto Innovation Acceleration Partners (TIAP) for early-stage funding and Lab150 access, and adMare BioInnovations for company-formation support.

The initiative's competitive position rests on the breadth of its institutional ecosystem and faculty footprint rather than proprietary technology. BBTV alumni outcomes include Twenty-nine Therapeutics (Health Canada first-in-human trial approval at UHN's Princess Margaret Cancer Centre, Terry Fox Research Institute grant) and Re:Pair Genomics (Hult Prize, $25,000 Tech@RBC Momentum Grant, CABHI Ignite cohort), demonstrating credible but early-stage translational throughput. PRiME's central product is thus its convening power and pipeline-generating capability across the Toronto precision medicine ecosystem, not a licensable technology asset.

Name

PRiME Next-Generation Precision Medicine at the University of Toronto

Legal name

PRiME Next-Generation Precision Medicine at University of Toronto

Website

https://prime.utoronto.ca

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

PRiME is the University of Toronto's institutional strategic initiative in next-generation precision medicine, aligning multidisciplinary research through three Precision X hubs (Aging, Oncology, Women's Health) and serving faculty, trainees, and biotech ventures in Toronto.

Ownership category

akta.pro rank

Product category

Precision Medicine Research and Training

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Colleges, Universities, and Professional Schools (6113)

akta.pro industry

PRIMARYEDAHAAAC

Public Research Universities with Academic Medical Centers (AMCs)

Education/Higher Education (Colleges & Universities)/Public Research Universities

SECONDARYHLAFAMAL

Clinical Research & Trial Central Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYEDAGANAJ

Healthcare & Clinical Professional Development (CME/CE)

Education/Educational Publishing & Learning Content/Professional Development & Training Materials

Keywords

• Precision medicine research
• Interdisciplinary biomedical research
• Biotech venture building
• Translational medicine training
• Academic research fellowships

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Institutional Strategic Initiative Funding: PRiME is funded as a strategic initiative of the University of Toronto, with support from institutional resources and strategic partnerships.
2. Research Funding and Grants: Program generates and distributes research funding through competitive programs like the BBTV Pitch Competition ($25,000 awards) and Fellowship programs, supported by sponsors and partners.
3. Donations and Philanthropy: The initiative accepts donations through the University of Toronto's donation platform, including specific chairs such as the Pamela and Paul Austin Chair in Precision and Regenerative Medicine.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

PRiME is the University of Toronto's institutional strategic initiative that coordinates multi-disciplinary research and training in next-generation precision medicine across three Precision X hubs (Precision Aging, Precision Oncology, Precision Women's Health). It delivers fellowship funding, PhD-level training through the Collaborative Specialization program, biotech venture-building workshops and pitch competitions, and an annual symposium that convenes researchers, clinicians, and industry partners.

Product overview

PRiME (Next-Generation Precision Medicine) is the University of Toronto's institutional strategic initiative in precision medicine, operating as a research coordination and training hub rather than a commercial product company. The initiative encompasses the Precision X Hubs (Precision Aging, Precision Oncology, Precision Women's Health), the Building a Biotech Venture Program for entrepreneurial training, the PRiME Fellowship Program for trainee support, the Collaborative Specialization for PhD training, and the Annual Symposium for knowledge exchange. These programs collectively address unmet needs in drug discovery, delivery, diagnostics, and disease biology through interdisciplinary collaboration between academia, industry, and healthcare partners.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision X Hubs Interdisciplinary research hubs focusing on Precision Aging, Precision Oncology, and Precision Women's Health, bringing together basic scientists, clinical researchers, biomedical engineers, innovators, and entrepreneurs to advance drug discovery, diagnostics, and disease biology.
• PRiME Fellowship Program A fellowship program providing financial support to outstanding trainees from PRiME faculty member labs at the University of Toronto, supporting multidisciplinary research focused on precision medicine solutions including drug discovery, diagnostics, and disease biology.
• Collaborative Specialization in Next-Generation Precision Medicine A PhD training program providing a cross-disciplinary approach bridging natural sciences and engineering with life sciences to address unmet challenges in human disease.
• Building a Biotech Venture Program A venture-building program that supports trainee teams from U of T and affiliated hospitals in developing biotech venture concepts through workshops, mentorship, and pitch competitions, with guidance on business canvas development, intellectual property, clinical translation, and early-stage investment, culminating in a pitch competition with up to $25,000 in research funding.
• PRiME Annual Symposium Annual symposium bringing together researchers, industry experts, investors, and policymakers to discuss advancements in precision medicine, featuring keynote speakers, panel discussions, poster sessions, and networking opportunities. The 7th Annual Symposium in 2026 welcomed nearly 200 trainees, faculty, industry experts, and researchers.

Quantifiable outcome

• Multiple BBTV winners have gone on to secure additional funding and recognition including Twenty-nine Therapeutics gaining Health Canada approval for clinical trials and Re:Pair Genomics securing $25,000 Tech@RBC Momentum Grant
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

19 partnerships are on record, tiered core, minor and flagship.

• Hospital for Sick Children (HSC)coreStrategic or Co-development Partner · 20 February 2026PRiME partners with The Hospital for Sick Children to announce annual PRiME HSC Fellows and collaborative research initiatives. SickKids researchers participate in symposia, fellowship programs, and joint research efforts.
• University Health Network (UHN)coreStrategic or Co-development Partner · 20 February 2026PRiME partners with UHN to announce annual PRiME UHN Fellows and facilitate joint research initiatives. UHN researchers including those from Toronto General Hospital Research Institute participate in PRiME programs.
• Frontier: A Versant Discovery EngineminorGTM or Marketing Partner · 20 February 2026Sponsor of 7th Annual Symposium. Frontier is a Versant Discovery Engine focused on advancing breakthrough discoveries in biotechnology.
• BayercoreGTM or Marketing Partner · 20 February 2026Bayer is a sponsor of PRiME's 7th Annual Symposium. Alberto Nobili, VP & Head of Bayer Co.Lab Cambridge, delivered an industry keynote on accelerating innovation from concept to clinic. Bayer Co.Lab Connect program offers pathways for global ecosystems to connect with Bayer.
• AmgencoreGTM or Marketing Partner · 20 February 2026Sponsor of 7th Annual Symposium. Amgen participates in industry panels with representatives including Chadwick King, AVP Research, Immunoengineering & Site Head, Amgen BC.
• Genome CanadaminorGTM or Marketing Partner · 20 February 2026Sponsor of 7th Annual Symposium, supporting PRiME's precision medicine initiatives and community building efforts.
• Ontario Bioscience Innovation Organization (OBIO)minorGTM or Marketing Partner · 20 February 2026Sponsor of 7th Annual Symposium. OBIO supports Ontario's bioscience ecosystem and innovation initiatives.
• STEMCELL TechnologiesminorGTM or Marketing Partner · 8 May 2025Supported 2025 BBTV Pitch Competition with prize package including product discounts, scientific support, training and more as part of commitment to supporting new biotechnology companies in Canada.
• Creative Destruction Lab (CDL)minorGTM or Marketing Partner · 8 May 2025Provided 1:1 advisory sessions for BBTV winners as part of competition prizes. CDL offers advisory support for early-stage ventures.
• NovartisminorGTM or Marketing Partner · 21 February 2025Sponsor of 6th Annual Symposium. John Tallarico, Global Head of Discovery Sciences at Novartis Biomedical Research, delivered industry keynote on targeted therapies.
• ModernaminorGTM or Marketing Partner · 21 February 2025Sponsor of 6th Annual Symposium and provided Best Poster Award. Supports emerging talent in precision medicine research.
• Collaborative Drug Discovery (CDD Vault)minorGTM or Marketing Partner · 21 February 2025Sponsor of 6th Annual Symposium, supporting PRiME's community building and knowledge sharing initiatives.
• Quantitative Biosciences Institute (QBI) - UCSFcoreStrategic or Co-development Partner · 8 November 2024Joint symposium co-organized by Nevan Krogan (QBI), Brian Shoichet, and Molly Shoichet (PRiME) on Quantitative Approaches to Drug Discovery and Precision Medicine, held in San Francisco.
• BioHubNet (Biomanufacturing Hub Network)coreStrategic or Co-development Partner · 6 May 2024BioHubNet is an immersive talent development program led by PRiME's Molly Shoichet, awarded $18.9 million in federal funding to address highly qualified personnel (HQP) shortage in biomanufacturing. PRiME Director serves as program lead along with co-leads from U of T and Toronto Metropolitan University.
• Toronto Innovation Acceleration Partners (TIAP)flagshipStrategic or Co-development Partner · 30 November 2023TIAP and PRiME announced strategic partnership to advance research to commercialization in Toronto. TIAP provides early-stage funding, Lab150 drug discovery program access, and connections to translational resources for PRiME-affiliated ventures.
• adMare BioInnovationscoreStrategic or Co-development Partner · 15 February 2023adMare BioInnovations partnered with PRiME to support building new Canadian life science companies and therapeutic products through advancement of precision medicine research and commercialization. adMare brings commercial expertise and resources to the academic partnership.
• Medicine by Design (CCRM)flagshipStrategic or Co-development Partner · 1 January 2020Medicine by Design created the Building a Biotech Venture program and continues as a central partner. The program supports teams from U of T and affiliated hospitals to translate regenerative and precision medicine research into viable startup ventures. Medicine by Design sponsors the $25,000 research funding award along with PRiME.
• Health Innovation Hub (H2i)coreStrategic or Co-development Partner · 1 January 2020H2i, led by Professor Paul Santerre, provides mentorship and venture development support for BBTV program participants. H2i is University of Toronto's health innovation hub embedded in the Faculty of Dentistry and Institute of Biomedical Engineering.
• Talk BoutiquecoreImplementation/ SI/ Consulting Partner · 1 January 2020Talk Boutique provides pitch coaching and presentation skills training for BBTV program finalists, helping teams refine their venture pitches for the competition.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Creative Destruction Lab (CDL): Toronto-based venture accelerator affiliated with U of T's Rotman School. Comparable as a U of T-affiliated program offering mentorship and seed-stage advisory to science-based startups; provides 1:1 advisory sessions for PRiME BBTV winners.
• Buck Institute for Research on Aging: Independent research institute focused on aging and age-related disease. Comparable as a specialty research organization addressing one of PRiME's Precision X hub areas (Precision Aging) with translational research focus.

Broad incumbents

• adMare BioInnovations: Canadian life sciences venture builder with academic and industry partnerships. Broad incumbent peer to PRiME as a national-scale, academic-facing translational biotech platform supporting company creation in Canada.
• Toronto Innovation Acceleration Partners (TIAP): U of T-affiliated accelerator providing Lab150 drug discovery program and commercialization funding. Broad incumbent peer as PRiME's commercialization partner; overlaps in supporting research-to-venture translation in Toronto.
• MaRS Discovery District: Toronto-based innovation hub supporting health, cleantech, and other ventures. Broad incumbent comparable to PRiME as a Toronto-centric academic-adjacent venture support ecosystem; less specialized in precision medicine but overlapping in biotech venture development.

Direct peers

• Icahn Institute for Precision Medicine at Mount Sinai: University-based precision medicine research institute at Mount Sinai focused on genomic-driven, multi-disease translational research with affiliated hospital networks. Directly comparable as a university-hosted, multi-disciplinary precision medicine coordination hub with clinical translation mandates.
• Ontario Institute for Cancer Research (OICR): Provincial cancer research institute in Ontario that partners with PRiME on fellowship programs. Directly comparable as a Canadian, publicly funded translational research initiative focused on precision oncology with academic and hospital network integration.
• UCSF Bakar Precision Medicine Center: University of California San Francisco's precision medicine center convening faculty and clinicians across therapeutic areas. Directly comparable to PRiME as an academic precision medicine hub with multi-disciplinary translational programs and industry engagement.
• Stanford Precision Health: Stanford Medicine's institutional precision health initiative bringing together engineering, biomedical, and clinical expertise. Directly comparable to PRiME as a top-tier university-hosted precision medicine platform leveraging interdisciplinary research.
• Knight Cancer Institute at Oregon Health & Science University: NCI-designated comprehensive cancer center with major precision oncology programs. Comparable to PRiME's Precision Oncology hub as a university-based translational oncology center focused on molecularly guided therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/UofTPRiME
• YouTubeyoutube.com/@primeuoft281
• LinkedInlinkedin.com/company/prime-uoft

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRiME Next-Generation Precision Medicine at the University of Toronto